ctDNA-Guided Surveillance After Colorectal Cancer Surgery Shows Major Increase in Curative Treatment for Recurrence
A newly published Phase III randomized trial has provided important evidence that circulating tumor DNA (ctDNA) can be used to make postoperative surveillance of colorectal cancer more responsive and potentially more curative. The FIND trial, published online in the Journal of Clinical Oncology in July 2026, tested whether repeated ctDNA testing could detect recurrent disease earlier than conventional CT-based follow-up.
The trial included patients with initially nonmetastatic colorectal cancer who had undergone complete surgical removal of their tumors. A total of 728 patients were randomized, with 363 assigned to ctDNA-guided surveillance and 365 to standard CT-based surveillance. After exclusions, 584 patients—289 in the ctDNA group and 295 in the control group—formed the modified intention-to-treat population.
The principle behind the approach is relatively straightforward. ctDNA consists of fragments of tumor-derived DNA that circulate in the bloodstream. After apparently successful surgery, the detection of such DNA can indicate molecular residual disease or an emerging recurrence before conventional imaging can clearly demonstrate a tumor.
In the FIND trial, patients assigned to the experimental arm underwent regular ctDNA methylation testing. A positive result triggered immediate CT imaging, while patients with negative results continued scheduled surveillance and repeated ctDNA testing. The strategy was designed to bring imaging forward when molecular evidence suggested that cancer was returning.
The most striking finding was not that ctDNA reduced the number of patients who developed recurrence. Recurrence rates were almost identical: 18.0% with ctDNA-guided surveillance versus 18.6% with standard surveillance. The major difference was what happened after recurrence was detected.
Among patients who experienced recurrence, 48.1% in the ctDNA-guided group received curative-intent metastasis-directed treatment, compared with only 23.6% in the standard-surveillance group. That represented a relative risk of 2.03, with the difference reaching statistical significance.
The researchers believe the explanation is earlier detection. Median time to clinical recurrence was 9.5 months in the ctDNA-guided group compared with 13.4 months in the conventional surveillance group, giving ctDNA surveillance a lead time of approximately 3.9 months.
That additional time can be particularly important in colorectal cancer because some recurrent tumors—especially limited metastases in the liver or lungs—can potentially be removed or treated with curative intent if discovered while disease remains limited.
The trial’s results support that possibility. Among patients whose recurrence was confined to the liver and/or lungs, curative resection was performed in 42.3% of patients in the ctDNA-guided arm versus 18.2% in the standard-surveillance arm. The ctDNA group also tended to have more favorable metastatic disease characteristics, including fewer lesions, smaller tumors and more frequently unilobar liver disease.
The findings are significant because postoperative surveillance has traditionally depended heavily on scheduled imaging and clinical assessment. CT scans, however, can miss very small-volume recurrent disease until it becomes radiologically apparent. ctDNA potentially provides a molecular warning system that can prompt imaging precisely when the probability of recurrence is rising.
The FIND trial was conducted across six academic medical centers in China and enrolled adults with stage I-III colorectal cancer who had undergone R0 resection and had no radiologically detectable distant metastases before surgery. The study therefore focused on patients who initially appeared to have potentially curable disease after surgery.
The results also need to be interpreted carefully. The trial has not yet demonstrated that ctDNA-guided surveillance improves overall survival. The investigators specifically state that longer follow-up is required to determine whether the increase in curative-intent treatment ultimately translates into better long-term survival.
This distinction is important. Detecting recurrence earlier and performing more metastasis-directed treatments are encouraging intermediate outcomes, but they do not automatically prove that patients will live longer. Mature disease-free and overall-survival results will therefore be critical before ctDNA-guided surveillance can be considered definitively superior to established follow-up strategies.
The FIND results nevertheless add to a rapidly developing body of evidence supporting ctDNA in colorectal cancer. Earlier randomized research, including the DYNAMIC trial in stage II colon cancer, showed that ctDNA could be used to guide postoperative chemotherapy decisions while substantially reducing chemotherapy use without compromising two-year recurrence-free survival. That study addressed treatment decisions rather than surveillance, but it helped establish ctDNA as a clinically meaningful marker of residual disease.
Other randomized work is also examining ctDNA-guided postoperative surveillance. The Danish IMPROVE-IT2 trial, for example, compares ctDNA-guided surveillance with conventional CT surveillance in stage III colorectal cancer and is designed around the hypothesis that molecular monitoring can identify recurrence earlier and increase the number of patients eligible for curative treatment. ClinicalTrials.gov currently lists the study as active but not recruiting.
The broader implication is that postoperative colorectal cancer surveillance could eventually become more individualized: rather than relying solely on a fixed imaging schedule, clinicians could combine conventional scans with a patient’s molecular disease signal and intensify investigation when ctDNA becomes positive.
For now, however, the FIND trial provides strong evidence that ctDNA-guided surveillance can detect recurrent colorectal cancer earlier and substantially increase the proportion of recurrent patients receiving potentially curative treatment. Whether that earlier intervention ultimately produces a meaningful survival advantage remains the crucial question awaiting longer follow-up.
